Amniotic & Placental Products
Amniotic Fluid, Membrane, and 'Placental' Injections Marketed for Sexual Health, Unproven and Often Noncompliant
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Regulated as HCT/Ps or drugs; many marketed products are noncompliant; none approved for ED
Reference only. Not medical advice.
What can go wrong
Infection risk from injected biological products, plus the possibility of contamination in inadequately manufactured preparations. As with exosomes, the deeper harms are financial and the delay of evidence-based ED care. No controlled evidence supports any benefit for erectile function, size, or performance.
This is something to take to a clinician. The Atlas can tell you what is known about amniotic & placental products in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Products derived from birth tissue, amniotic fluid, amniotic membrane, chorion, and 'placental' preparations, are marketed by some clinics as regenerative injections for erectile dysfunction and sexual 'rejuvenation,' promoted as rich in growth factors and (falsely, when processed) 'living stem cells.' The FDA regulates human cells, tissues, and cellular/tissue-based products (HCT/Ps) under 21 CFR 1271; products that are more-than-minimally manipulated, used non-homologously, or make drug claims require premarket approval, and many marketed birth-tissue products fail these criteria and are effectively unapproved biologics. There is no controlled evidence that amniotic or placental products treat ED, enlarge the penis, or improve performance. Processed (irradiated, cryopreserved) products contain few or no viable cells, undercutting the 'stem cell' pitch.
'Birth-tissue' regenerative claims with no sexual-health evidence and a shaky regulatory footing.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Birth-tissue products are promoted as concentrated sources of growth factors, cytokines, and extracellular-matrix components that promote healing and angiogenesis. Any genuine regenerative effect would be paracrine and matrix-mediated; the 'living stem cell' framing is generally inaccurate for the commercially processed, sterilized products actually sold. For sexual health, no mechanism has been validated in controlled human study.
The catch: 'stem cells' that aren't, on regulatory thin ice
Manufacturers and clinics frequently imply these products deliver live stem cells, but standard processing (cryopreservation, irradiation) leaves few or no viable cells, so the advertised mechanism is largely absent. The FDA has repeatedly warned that many birth-tissue products marketed for injection are unapproved drugs when they are more-than-minimally manipulated, used non-homologously, or promoted with disease claims. Applied to ED, these products combine an unproven indication with a frequently noncompliant regulatory posture.
What people get wrong
Often saidAmniotic/placental injections deliver living stem cells
ActuallyProcessed products typically contain few or no viable cells; the 'stem cell' claim is usually inaccurate.
Often saidThese are approved regenerative treatments
ActuallyNone is FDA-approved for ED; many are noncompliant HCT/Ps or unapproved drugs.
Often saidThey restore erectile tissue
ActuallyThere is no controlled human evidence for ED, enlargement, or performance.
Who profits, and who pushes back
US FDA
Unapproved products from human cells or tissues, including some marketed as amniotic or placental, can pose serious risks and make unproven claims.
Birth-tissue product distributors and the clinics injecting them collect the revenue; as with exosomes, the category markets around an approval pathway it does not satisfy.
What we do not know
- Do any characterized birth-tissue matrix products have a legitimate, testable role in tissue repair?
- Will enforcement address the sexual-health marketing of these products specifically?
At a glance
- Regulatory basis
- HCT/P (21 CFR 1271) or drug/biologic
- Approved for ED
- None
- 'Living stem cells' claim
- False for processed products (few/no viable cells)
- Controlled ED evidence
- None
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Amniotic & Placental Products. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.